{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:17:31Z","timestamp":1731129451315,"version":"3.28.0"},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2023.50999","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:31:06Z","timestamp":1705681866000},"page":"e2350999","source":"Crossref","is-referenced-by-count":0,"title":["Progress Toward Cardiac Risk Reduction With the Evolution of Pediatric Hodgkin Lymphoma Therapy"],"prefix":"10.1001","volume":"7","author":[{"given":"Kasey J.","family":"Leger","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Seattle Children\u2019s Hospital, University of Washington, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari K.","family":"Narayan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego"},{"name":"Rady Children\u2019s Hospital San Diego, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"1","key":"zic230209r1","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children\u2019s oncology group trials.","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"},{"issue":"29","key":"zic230209r2","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"zic230209r3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51062","article-title":"Late cardiac toxic effects associated with treatment protocols for Hodgkin lymphoma in children.","volume":"7","author":"Lo","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"20","key":"zic230209r4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1200\/JCO.20.01186","article-title":"Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the Childhood Cancer Survivor Study.","volume":"39","author":"Oeffinger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"zic230209r5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.HS9.0000890964.54059.2c","article-title":"T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma.","volume":"6","author":"Moskowitz","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"zic230209r6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis.","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"zic230209r7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","article-title":"Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction.","volume":"98","author":"Hahn","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"zic230209r8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42071","article-title":"A systematic review of myocarditis induced by immune checkpoint inhibitors: how concerning is the most common cardiotoxicity of immune checkpoint inhibitors?","volume":"15","author":"Moradi","year":"2023","journal-title":"Cureus"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814096\/leger_2024_ic_230209_1704921096.16414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:50:03Z","timestamp":1731084603000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50999","relation":{},"ISSN":["2574-3805"],"issn-type":[{"type":"electronic","value":"2574-3805"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}